Global information about the BIMERVAX® COVID-19 HIPRA’s vaccine, adjuvanted recombinant protein vaccine, based on a receptor-binding domain fusion heterodimer.

The approval status of the BIMERVAX® COVID-19 vaccine varies worldwide. In countries where the vaccine has not been approved by the relevant regulatory authority or regulatory process, you will not find information about it on this site. This site will be updated as more information on the regulatory status of BIMERVAX® in other countries becomes available.